Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
AbbVie Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Incyte Corp
IO Biotech ApS
Italfarmaco SpA
Kartos Therapeutics Inc
Merganser Biotech Inc
NMS Group SpA
PharmaEssentia Corp
Protagonist Therapeutics Inc
Sino Biopharmaceutical Ltd
Polycythemia Vera - Drug Profiles
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KRT-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitoclax dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TQ-05105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Nov 25, 2019: Data from Incyte’s Oncology Portfolio including ruxolitinib phosphate accepted for presentation at the 61st Annual ASH Meeting
Oct 31, 2019: Protagonist doses first patient in Phase II study of PTG-300
Feb 21, 2019: PharmaEssentia and AOP Orphan receive EU approval of Besremi (Ropeginterferon Alfa-2b) for treatment of polycythemia Vera (PV) in EU
Dec 13, 2018: AOP Orphan Pharmaceuticals receives positive CHMP opinion for Besremi for the treatment of adult patients with previously untreated CD30+ stage IV Hodgkin Lymphoma in combition with AVD
Dec 05, 2018: PharmaEssentia updates progress of Ropeginterferon Alfa-2b clinical program
Nov 15, 2018: AOP Orphan is the winner of the MERCUR Innovation Award in the category Life Science for the clinical development project “Ropeginterferon a-2b”
Nov 02, 2018: Novartis to present data on Jakavi at 2018 ASH annual meeting
Jun 15, 2018: Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
Jun 11, 2018: AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
Dec 10, 2017: Four-Year Phase 3 Data Alysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients with Polycythemia Vera
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting
Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Polycythemia Vera, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019


List of Tables


Number of Products under Development for Polycythemia Vera, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Polycythemia Vera - Pipeline by AbbVie Inc, H2 2019
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H2 2019
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Polycythemia Vera - Pipeline by Gilead Sciences Inc, H2 2019
Polycythemia Vera - Pipeline by Incyte Corp, H2 2019
Polycythemia Vera - Pipeline by IO Biotech ApS, H2 2019
Polycythemia Vera - Pipeline by Italfarmaco SpA, H2 2019
Polycythemia Vera - Pipeline by Kartos Therapeutics Inc, H2 2019
Polycythemia Vera - Pipeline by Merganser Biotech Inc, H2 2019
Polycythemia Vera - Pipeline by NMS Group SpA, H2 2019
Polycythemia Vera - Pipeline by PharmaEssentia Corp, H2 2019
Polycythemia Vera - Pipeline by Protagonist Therapeutics Inc, H2 2019
Polycythemia Vera - Pipeline by Sino Biopharmaceutical Ltd, H2 2019
Polycythemia Vera - Dormant Projects, H2 2019
Polycythemia Vera - Discontinued Products, H2 2019